Статья
МЕСТО СИСТЕМНОГО ТРОМБОЛИЗИСА В СОВРЕМЕННОЙ РЕПЕРФУЗИОННОЙ ТЕРАПИИ ИНФАРКТА МИОКАРДА
В аналитической статье кратко представлена история тромболитической терапии при инфаркте миокарда, рассмотрены преимущества и ограничения современных методов реперфузинного лечения. Несмотря на доминирующее положение первичных чрескожных внутрикоронарных вмешательств, тромболитическая терапия остается важнейшим элементом начального ведения многих больных. Ее использование актуально для России, где наличие труднодоступных или малонаселенных областей, городов с неудачной транспортной инфраструктурой и проблемами организации здравоохранения не позволяет реализовать оптимальную инвазивную стратегию в требуемый временной интервал. Привлечено внимание к улучшению возможностей тромболитической терапии за счет догоспитального тромболизиса и широкого использования фармакоинвазивного подхода.
1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
2. Antman EM, Braunwald E. ST elevation myocardial infarction: Pathology, Pathophysiology and Clinical Features in Braunwald's Heart Disease — A textbook of Cardiovascular Medicine. 8th Edition, Published by Elsevier 2008;1210.
3. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619.
4. O Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 2013; 61: e78-140.
5. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012, 308 (10), 998-1006.
6. Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries, Eur Heart J, 2014.
7. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
8. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
9. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous fibrinolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
11. The GUSTO Investigators. An international randomized trial comparing four fibrinolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
12. GUSTO III investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
13. Assessment of the safety and efficacy of a New Thrombolytic Investigators. Single bolus tenecteplase compared with front loaded alteplase in acute myocardial infarction: the ASSENT- 2 double blind randomized trial. Lancet 1999; 354: 716-722.
14. Markin SS, Semenov AM, Markov VA, et al. Study of new native drug of fortelesyne in patients with acute myocardial infarction. Siberian medical journal 2012; 27 (1): 27-32. Russian (Маркин C. C., Семенов А. М., Марков В. А. и соавт. Исследование нового отечественного препарата фортелезин у больных с острым инфарктом миокарда. Сибирский медицинский журнал 2012; 27 (1): 27-32).
15. Van de Werf F, et al. Management of acute myocardial infarction in patients presenting with persistent ST elevation. Eur Heart J 2008; 29: 2909-45.
16. Boresma E, Mass ACP, Decker JW, et al. Early thrombolytic therapy in acute myocardial infarction. Lancet 1996; 348: 771-5.
17. Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95: 2508-16.
18. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92: 2811-8.
19. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993; 88: 1361-74.
20. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous fibrinolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
21. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate fibrinolysis in acute myocardial infarction. Final results of the randomized national multicenter trial-PRAGUE-2. Eur Heart J 2003; 24: 94-104.
22. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-42.
23. Mehta RH, Bufalino VJ, Pan W, et al. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. Am Heart J 2008; 155: 1059-67.
24. Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI) -3/4 analysis. Circulation 2005; 111:761-7.
25. Kalla K, Christ G, Karnik R, et al. Vienna STEMI Registry Group. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction. Circulation 2006; 113: 2398-405.
26. Boersma E. Primary Coronary Angioplasty vs.Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779-88.
27. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital fibrinolysis for acute myocardial infarction: A meta-analysis. J Am Med Assoc 2000; 283: 2686-92.
28. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. on behalf of the CAPTIM study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-29.
29. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-6.
30. Danchin N, Blanchard D, Steg PG, et al. for the USIC 2000 investigators. Impact of prehospital fibrinolysis for acute myocardial infarction on 1-year outcome. Results from the French nationwide USIC 2000 registry. Circulation 2004; 110: 1909-15.
31. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009;30:1598-606.
32. De Luca G, Suryapranata H, Zijlstra F, et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42: 991-7.
33. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute of delay counts. Circulation 2004; 109: 1223-5
34. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 2005; 95: 100-1.
35. Terkelsen CJ, Lassen JF. Treatment delays in ST elevation myocardial infarction. Br Med J 2008; 336: 401-2.
36. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114:2019-25.
37. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase- facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569-78.
38. Ellis SG, Tendera M, de Belder MA, et al; FINESSE Investigators. Facilitated PCI in patients with STelevation myocardial infarction. N Engl J Med 2008; 358: 2205-17.
39. Gershlick AH, Stephens-Lloyd A, Hughes S, et al; REACT Trial Investigators. Rescue angioplasty after failed fibrinolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353: 2758-68.
40. Danchin N, Coste P, Ferrires J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008; 118: 268-76.
41. Scheller B, Hennen B, Hammer B et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 634-41.
42. Fernandez-Avilis F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-53.
43. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction. J Am Coll Cardiol 2005;46:417-24.
44. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after fibrinolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicenter trial. Lancet 2008; 371: 559-68.
45. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360: 2705-18.
46. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after fibrinolysis in acute myocardial infarction in areas with very long transfer distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of STelevation myocardial infarction). J Am Coll Cardiol 2010; 55: 102-10.
47. Huber K, Goldstein P, Danchin N, et al. Network models for large cities: the European experience. Heart 2010; 96: 164-9.
48. Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010; 160: 30-35.
49. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or Primary PCI in ST-segment elevation Myocardial infarction. N Engl J Med 2013; 368: 1379-87.
50. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. J Am Med Assoc 2010; 303: 2148-55.